PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Poly-adenosyl-ribose polymerase (PARP) inhibitors represent a significant advancement in treating ovarian and breast cancers.
• Their efficacy is particularly pronounced in patients with pathogenic BRCA mutations.

Purpose of the Study:

• To review the clinical trials and approved indications for PARP inhibitors in ovarian and breast cancers.
• To examine the pharmacological differences, emerging resistance mechanisms, and future clinical questions for PARP inhibitors.

Main Methods:

• Review of clinical trial data and published literature on PARP inhibitors.
• Analysis of pharmacological properties and toxicity profiles.
• Examination of resistance mechanisms and future research directions.

Main Results:

• Distinct clinical trial designs have led to specific indications for different PARP inhibitors.
• Emerging toxicity patterns suggest variations in normal tissue tolerance among PARP inhibitors.
• PARP inhibitor resistance is a growing concern in advanced ovarian and breast cancer treatment.

Conclusions:

• PARP inhibitors have transformed treatment for BRCA-mutated ovarian and breast cancers.
• Understanding differences in indications, toxicities, and resistance is crucial for optimizing their use.
• Further research is needed to address key clinical questions and advance PARP inhibitor therapy.